Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease

doi:10.3748/wjg.v28.i26.3243

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 26

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6554)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-3) series.

Item

Count

PDF

428

WORD

HTML

3895

Figures (1-5)

346

Tables (1-3)

284

Sum=5019

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

365

Download

1170

Sum=1535

Jul 14, 2022 (publication date) through Oct 21, 2024

Times Cited of This Article

Times Cited (19)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Jul 14, 2022; 28(26): 3243-3257
Published online Jul 14, 2022. doi: 10.3748/wjg.v28.i26.3243

Table 3 Circulating interleukin levels in patients enrolled in the study and included in groups treated with the sodium-glucose co-transporter-2 inhibitors or other glucose lowering drugs before (T0) and after 1 wk of treatment (T1)

Variable	SGLT2-I (n = 26)		OTHER (n = 26)		Fisher’s test (1, 100)
Variable	T0	T1	T0	T1	Time	Treatment	Interaction
IL-1α (pg/mL)	1.35 ± 1.64	1.58 ± 1.30	1.44 ± 1.88	1.59 ± 1.56	0.373	0.026	0.016
IL-1β (pg/mL)	9.90 ± 2.39	7.31 ± 3.51^e	8.84 ± 2.54	9.15 ± 2.42	4.455^a	0.521	7.207^b
IL-2 (U/mL)	≤ 0.5	≤ 0.5	≤ 0.5	≤ 0.5	-	-	-
IL-4 (pg/mL)	5.39 ± 4.20	8.54 ± 3.51^d	4.89 ± 3.54	5.94 ± 3.66	8.207^b	4.471^a	2.052
IL-6 (pg/mL)	9.41 ± 4.21	6.92 ± 1.98	11.4 ± 5.41	13.7 ± 9.01^h	0.007	15.4^c	4.516^a
IL-8 (pg/mL)	428 ± 216	409 ± 271	412 ± 296	449 ± 204	0.338	0.060	0.327
IL-10 (pg/mL)	1.33 ± 1.02	2.31 ± 1.12^e	1.29 ± 1.06	1.32 ± 1.04^g	5.894^a	6.130^a	5.214^a
TNF (pg/mL)	6.82 ± 3.02	4.61 ± 2.01^d	7.94 ± 3.14	7.81 ± 3.56^g	3.989^a	13.59^c	3.151
VEGF (pg/mL)	262 ± 162	142 ± 109^d	244 ± 201	268 ± 147^f	2.393	3.029	5.384^a
IFN-γ (pg/mL)	0.53 ± 0.23	0.57 ± 0.57	0.50 ± 0.39	0.61 ± 0.44	0.809	0.004	0.176
MCP-1 (pg/mL)	411 ± 168	291 ± 156	389 ± 154	414 ± 184^f	2.131	2.408	4.964^a
EGF (pg/mL)	25.7 ± 13.7	22.2 ± 12.1	24.9 ± 20.1	23.6 ± 18.6	0.553	0.009	0.116

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

^dP < 0.05 vs sodium-glucose co-transporter-2 inhibitor T0.

^eP < 0.01 vs sodium-glucose co-transporter-2 inhibitor T0.

^fP < 0.05 vs sodium-glucose co-transporter-2 inhibitor T1.

^gP < 0.01 vs sodium-glucose co-transporter-2 inhibitor T1.

^hP < 0.001 vs sodium-glucose co-transporter-2 inhibitor T1.

Data are expressed as mean ± SD. Statistical differences were assessed by two-way analysis of variance. VEGF: Vascular endothelial growth factor; MCP-1: Monocyte chemoattractant protein-1; EGF: Epidermal growth factor; SGLT2-I: Sodium-glucose co-transporter-2 inhibitor; OTHER: Other glucose lowering drug; IL: Interleukin; TNF: Tumor necrosis factor; IFN: Interferon.

Citation: Bellanti F, Lo Buglio A, Dobrakowski M, Kasperczyk A, Kasperczyk S, Aich P, Singh SP, Serviddio G, Vendemiale G. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease. World J Gastroenterol 2022; 28(26): 3243-3257
URL: https://www.wjgnet.com/1007-9327/full/v28/i26/3243.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i26.3243